HbA1C และ Fasting glucose มากกว่า 240 mg/dl โดยไม่ทราบสาเหตุThe treat-to-target design of the trials included the same titration algorithms for the IDeg and IGlar treatmentgroups to enable patients to achieve a prebreakfast blood glucose calibrated to a PG target of <5.0 mmol/L (<90 mg/dL) (23-29). Consequently, similar glycemic control was achieved with both treatments, and noninferiority of IDeg to IGlar in HbA1c reduction was confirmed in all trials (30). The trials were not designed to test superiority in glycemic control
การแปล กรุณารอสักครู่..